Tetra Discovery Partners LLC is a leader is the chemical design of inhibitors of PDEs in the brain involved in cognition/memory, depression and inflammation, called PDE4B and PDE4D subtype enzymes. Tetra uses a structure-guided drug design chemistry approach to discover mechanistically novel, allosteric inhibitors of phosphodiesterase 4 (PDE4) subtypes.
Tetra is targeting the function of PDE4s, to enhance memory formation in brain neurons, nerve dendrites involved in depression, and brain microglia involved in brain inflammation. Tetra’s drug discovery platform can also be used to develop novel treatments for peripheral diseases where PDEs are attractive drug targets.
Latest NewsAugust 1, 2013
Tetra receives $3 million Phase II SBIR award for work on depression drug. Read this articleJune 2, 2013
Tetra receives a Small Company Innovation Program (SCIP) award for work on depression drug. Read this articleJune 19, 2012
Tetra receives major funding to discover a drug for mild cognitive impairment.Read this article
- No categories